 Mandy Renee Sakamoto
| Title | Assistant Professor |
|---|
| Institution | University of Colorado Denver - Anschutz Medical Campus |
|---|
| Department | SOM-MED |
|---|
|
|
|
 Bibliographic
-
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan; 199:108040. PMID: 39615411.
-
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC. JTO Clin Res Rep. 2024 Feb; 5(2):100637. PMID: 38361741.
-
Sakamoto M, Patil T. Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance. NPJ Precis Oncol. 2023 Jun 08; 7(1):56. PMID: 37291202.
-
Sakamoto M, Patil T. MET alterations in advanced non-small cell lung cancer. Lung Cancer. 2023 04; 178:254-268. PMID: 36924573.
-
Sakamoto M, Jimeno A. Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer. Drugs Today (Barc). 2023 Mar; 59(3):169-177. PMID: 36847625.
-
Azelby CM, Sakamoto MR, Bowles DW. ROS1 Targeted Therapies: Current Status. Curr Oncol Rep. 2021 06 14; 23(8):94. PMID: 34125313.
-
Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 01 06; 19(1):29-38. PMID: 33406490.
-
Sakamoto MR, Honce JM, Lindquist DL, Camidge DR. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer. 2019 03; 20(2):e133-e136. PMID: 30578110.
-
Eastman KL, Lutton MC, Raugi GJ, Sakamoto MR, McDowell JA, McFarland LV, Reiber GE. A teledermatology care management protocol for tracking completion of teledermatology recommendations. J Telemed Telecare. 2012 Oct; 18(7):374-8. PMID: 23086980.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2012 | 1 | | 2018 | 1 | | 2021 | 2 | | 2023 | 3 | | 2024 | 2 |
To return to the timeline, click here.
|
Sakamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|